Literature DB >> 2259404

Hemorrhagic pituitary adenomas: clinicopathological features and surgical treatment.

B Fraioli1, V Esposito, L Palma, G Cantore.   

Abstract

Forty-five (9.9%) of 453 pituitary adenomas operated on between January 1973 and November 1988 demonstrated hemorrhagic changes at surgery: 24 had a blood collection, 12 had a blood collection associated with hemorrhagic necrosis, and 9 had hemorrhagic necrosis. Thirteen patients (28.9%) experienced the acute symptoms of pituitary apoplexy, whereas another 32 had an "asymptomatic" hemorrhage, that is, the clinical course was comparable to an uncomplicated adenoma. Nineteen tumors (42.2%) showed marked suprasellar extension, 8 (17.8%) showed moderate extension, and 11 (24.5%) showed slight extension; another 2 (4.4%) were laterosellar and 5 (11.1%) were intrasellar. Invasive behavior was present in 32 cases (71.1%) and this may suggest another hypothesis to explain the pathogenesis of tumoral hemorrhage. The incidence of hemorrhagic complications in invasive adenomas with marked suprasellar extension was particularly impressive; therefore, we do not suggest preoperative bromocriptine treatment in this type of tumor. Two of 14 patients operated on by the transcranial route died after surgery, whereas there was no operative mortality in the 31 patients operated on by the transsphenoidal route. It proved advantageous to operate as early as possible, even during the acute phase of pituitary apoplexy. The transsphenoidal approach gave the best results, but to achieve satisfactory late results multidisciplinary treatment was necessary, namely, postoperative radiotherapy in 23 patients, bromocriptine in 12, and endocrine replacement therapy in almost all. In an average follow-up period of 6.2 years, 5 (11.1%) symptomatic recurrences were observed.

Entities:  

Mesh:

Year:  1990        PMID: 2259404

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  16 in total

1.  Primary chronic intrasellar haematoma: a case report.

Authors:  K Saito; M Takayasu; A Akabane; H Okabe; K Sugita
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

2.  Visual outcome after transsphenoidal surgery in patients with pituitary apoplexy.

Authors:  Ju-Wan Seuk; Choong-Hyun Kim; Moon-Sul Yang; Jin-Hwan Cheong; Jae-Min Kim
Journal:  J Korean Neurosurg Soc       Date:  2011-06-30

3.  The supine position for transsphenoidal surgery.

Authors:  B Fraioli; V Esposito; G Liccardo; R Giuffrè; G Cantore
Journal:  Neurosurg Rev       Date:  1994       Impact factor: 3.042

4.  Arrested puberty associated with apoplectic prolactinoma in a male adolescent.

Authors:  A Kulah; C Erel; M Memis; A Sav
Journal:  Childs Nerv Syst       Date:  1995-02       Impact factor: 1.475

5.  Pediatric ischemic stroke from an apoplectic prolactinoma.

Authors:  Rebecca A Kasl; Joshua Hughes; Anthony M Burrows; Fredric B Meyer
Journal:  Childs Nerv Syst       Date:  2015-05-07       Impact factor: 1.475

6.  Spontaneous remission of Cushing's disease after disappearance of a microadenoma attached to the pituitary stalk.

Authors:  Analía B Pignatta; Adriana G Díaz; Reynaldo M Gómez; Oscar D Bruno
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

7.  Surgical management of giant pituitary tumours--a review of 30 cases.

Authors:  A Goel; T Nadkarni
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

Review 8.  Pituitary apoplexy presenting as Addisonian crisis after coronary artery bypass grafting.

Authors:  Angela Feazel Mattke; John R Vender; Mark R Anstadt
Journal:  Tex Heart Inst J       Date:  2002

Review 9.  Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer.

Authors:  Yannis Guerra; Evelyn Lacuesta; Francisco Marquez; P B Raksin; Manuel Utset; Leon Fogelfeld
Journal:  Pituitary       Date:  2010       Impact factor: 4.107

10.  Pituitary apoplexy in acromegaly, a long-term follow-up study in two patients.

Authors:  F Roelfsema; G van den Berg; H van Dulken; J D Veldhuis; S M Pincus
Journal:  J Endocrinol Invest       Date:  1998-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.